We use cookies to ensure our site functions properly and to store limited information about your usage. You may give or withdraw consent at any time. To find out more, read our privacy policy and cookie policy.
Manage Cookies
A cookie is information stored on your computer by a website you visit. Cookies often store your settings for a website, such as your preferred language or location. This allows the site to present you with information customized to fit your needs. As per the GDPR law, companies need to get your explicit approval to collect your data. Some of these cookies are ‘strictly necessary’ to provide the basic functions of the website and can not be turned off, while others if present, have the option of being turned off. Learn more about our Privacy and Cookie policies. These can be managed also from our cookie policy page.
Strictly necessary cookies(always on):
Necessary for enabling core functionality. The website cannot function properly without these cookies. This cannot be turned off. e.g. Sign in, Language
Analytics cookies:
Analytical cookies help us to analyse user behaviour, mainly to see if the users are able to find and act on things that they are looking for. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. Tools used: Google Analytics
Patients’ experiences during treatment with Immunotherapy
Share Patients’ experiences during treatment with Immunotherapy on FacebookShare Patients’ experiences during treatment with Immunotherapy on TwitterShare Patients’ experiences during treatment with Immunotherapy on LinkedinEmail Patients’ experiences during treatment with Immunotherapy link
Immunotherapy is a cancer treatment that helps your immune system recognise and fight off cancer cells. Immune Checkpoint Inhibitors (ICIs) are a type of Immunotherapy that block proteins that stop the immune system from attacking cancer cells.
Immunotherapy can be used to treat many different types of cancer. This study is looking at patients with hepatobiliary cancers ( liver (HCC), pancreas, biliary system) who are being treated with Immune Checkpoint Inhibitors.
We are shaping a future study and would like to hear your thoughts on the current proposal.
If you are or have been treated with Immune Checkpoint Inhibitors for hepatobiliary cancers or any other type of cancer (or you are a carer of someone in this position) please:
Get in touch if you would like to be part of an online workshop to help shape the study.
Vouchers will be provided for your time.
We are looking at the following dates:
Wednesday 15thJuly 6-7.30pm
Monday 27th July 12:30-02:00 pm
Friday 31st July 10-11.30am
Email [email protected] to register your interest and state your availability.
Thank your time and interest in this research.
Immunotherapy is a cancer treatment that helps your immune system recognise and fight off cancer cells. Immune Checkpoint Inhibitors (ICIs) are a type of Immunotherapy that block proteins that stop the immune system from attacking cancer cells.
Immunotherapy can be used to treat many different types of cancer. This study is looking at patients with hepatobiliary cancers ( liver (HCC), pancreas, biliary system) who are being treated with Immune Checkpoint Inhibitors.
We are shaping a future study and would like to hear your thoughts on the current proposal.
If you are or have been treated with Immune Checkpoint Inhibitors for hepatobiliary cancers or any other type of cancer (or you are a carer of someone in this position) please:
Get in touch if you would like to be part of an online workshop to help shape the study.
Vouchers will be provided for your time.
We are looking at the following dates:
Wednesday 15thJuly 6-7.30pm
Monday 27th July 12:30-02:00 pm
Friday 31st July 10-11.30am
Email [email protected] to register your interest and state your availability.
Thank you for sharing your story with us. Please sign up to stay in touch. This way you will get an email from us when we have a new project on the platform.
CLOSED: This discussion has concluded.
Share My wife's long history of HPV 16+ head & neck cancer on FacebookShare My wife's long history of HPV 16+ head & neck cancer on TwitterShare My wife's long history of HPV 16+ head & neck cancer on LinkedinEmail My wife's long history of HPV 16+ head & neck cancer link
My wife, Suzanne, was first treated in 2010 at the St. Lukes Cancer Centre, Royal Surrey County Hospital Guildford for SCC HPV16+ right tonsil and cervical lymph nodes, undergoing chemo & RT (60 Gys) followed by radical neck dissection. She recovered well until 2017.
She had a recurrence of the same type of cancer in 2017 (late diagnosis) this time in the nasopharyngeal space. It was not operable as the tumour was wrapped around the carotid artery. She consented to having a high-risk treatment of more RT (60Gys) & chemo at The Royal Marsden, the treatment area overlapping partially with... Continue reading
My wife, Suzanne, was first treated in 2010 at the St. Lukes Cancer Centre, Royal Surrey County Hospital Guildford for SCC HPV16+ right tonsil and cervical lymph nodes, undergoing chemo & RT (60 Gys) followed by radical neck dissection. She recovered well until 2017.
She had a recurrence of the same type of cancer in 2017 (late diagnosis) this time in the nasopharyngeal space. It was not operable as the tumour was wrapped around the carotid artery. She consented to having a high-risk treatment of more RT (60Gys) & chemo at The Royal Marsden, the treatment area overlapping partially with that in 2010. This eliminated the tumour but had a devastating impact on oral tissue, salivary function, swallow and jaw fibrosis which still requires daily management to this day.
In 2019 she had a recurrence in the left cervical nodes and had a further neck dissection at the Marsden followed by a short course of EBT at the Royal Surrey County Hospital.
In mid 2020 she was diagnosed with a recurrence in the base of tongue and started immunotherapy treatment (Pembrolizumab) at the RSCH in September 2020. This treatment continued for 2 ½ years and virtually eliminated the tumour. However, towards the end of treatment it resulted in a severe adverse effect that destroyed pancreatic function resulting in exocrine pancreatic insufficiency and type 3C diabetes.
Unfortunately, a localised spread to the epiglottis was discovered in December 2022 and the RSCH referred her back to the Marsden for participation in a suitable clinical trial. In April 2023 she started on a clinical trial of Cemiplimab (Regeneron) immunotherapy combined with an experimental vaccine (ISA 101b) targeting the specifics of two HPV 16+ tumour protein expressions. This was planned to be a two-year trial with treatment on a three-weekly cycle, along with clinic appointments, blood tests and regular scans. However, the sponsors closed the trial to new entrants but her treatment is continuing on a compassionate basis. In May 2024 her treatment was suspended while while numerous tests for possible ulcerative colitis caused by the immunotherapy were undertaken at RSCH. Ultimately U/C and other inflammatory side effects were ruled out and treatment re-commenced in August 2024.
Share Immunotherapy for Stage 4 Head and Neck Cancer on FacebookShare Immunotherapy for Stage 4 Head and Neck Cancer on TwitterShare Immunotherapy for Stage 4 Head and Neck Cancer on LinkedinEmail Immunotherapy for Stage 4 Head and Neck Cancer link
After chemo-radiation treatment for HPV-related head and neck cancer in 2020, the cancer had unfortunately spread, and in 2021 I was diagnosed with Stage 4 cancer, with 6 tumours across both lungs.
I had biomarkers for PDL1(?) checked out, and they showed that I would be a suitable patient for immunotherapy, specifically Pembrolizumab. I was given an infusion in a cancer ward every 6 weeks, and I had CT scans every 3 months.
The Pembro worked quickly to reduce the size of the tumours and then over the next 2-year period they gradually shrunk to a small size.
After chemo-radiation treatment for HPV-related head and neck cancer in 2020, the cancer had unfortunately spread, and in 2021 I was diagnosed with Stage 4 cancer, with 6 tumours across both lungs.
I had biomarkers for PDL1(?) checked out, and they showed that I would be a suitable patient for immunotherapy, specifically Pembrolizumab. I was given an infusion in a cancer ward every 6 weeks, and I had CT scans every 3 months.
The Pembro worked quickly to reduce the size of the tumours and then over the next 2-year period they gradually shrunk to a small size.
As Pembro was only licensed for 2 years, I came off treatment in 2023 and am now scanned every 3 months to check that the cancer has not spread further.
So my experience of immunotherapy has been really, really good. I had few, if any, side effects (apart from fatigue for a day or so after my infusion). This meant that I could continue with my passion of running ultra-marathons.
But I know that I was very lucky (i) in being able to have immunotherapy treatment, (ii) that it does not cause me any major side effects, and (iii) the treatment worked to show that by the end of two years scans revealed I have had a complete radiological response.
I wrote up about my experiences with immunotherapy here, if any one would like more information
My main worry now is if, or when, the tumours do regrow, or new ones appear, how will I be treated? No one seems sure of my eligibility to go back onto Pembro, so that is an uncertainty that does worry me.
Share Nataliya09 on FacebookShare Nataliya09 on TwitterShare Nataliya09 on LinkedinEmail Nataliya09 link
I've had 12 rounds of immunotherapy - started in November 2023, after 10 rounds of chemotherapy. I have been explained all side effects to expect, and given a brochure with information about the drug used in the treatment. I'm having treatment once every three weeks. So far, I'm tolerating the immunotherapy much better than chemo, with practically no side effects (I have neuropathy but it seems to be a chemo side effect). The immunotherapy seems to work well for me at the moment.
I've had 12 rounds of immunotherapy - started in November 2023, after 10 rounds of chemotherapy. I have been explained all side effects to expect, and given a brochure with information about the drug used in the treatment. I'm having treatment once every three weeks. So far, I'm tolerating the immunotherapy much better than chemo, with practically no side effects (I have neuropathy but it seems to be a chemo side effect). The immunotherapy seems to work well for me at the moment.
